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Abstract We report a new member of the von Willebrand factor
A-domain protein superfamily, WARP (for von Willebrand
factor A-domain-related protein). The full-length mouse WARP
cDNA is 2.3 kb in size and predicts a protein of 415 amino
acids which contains a signal sequence, a VA-like domain, two
fibronectin type III-like repeats, and a short proline- and
arginine-rich segment. WARP mRNA was expressed predomi-
nantly in chondrocytes and in vitro expression experiments in
transfected 293 cells indicated that WARP is a secreted
glycoprotein that forms disulphide-bonded oligomers. We con-
clude that WARP is a new member of the von Willebrand factor
A-domain (VA-domain) superfamily of extracellular matrix
proteins which may play a role in cartilage structure and
function. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The extracellular matrix (ECM) is a complex mixture of
collagens, non-collagenous glycoproteins, and proteoglycans
that interact to provide a structural sca¡old as well as speci¢c
cues for the maintenance, growth and di¡erentiation of cells
and tissues. The protein cores of a large number of ECM
molecules are composed of di¡erent combinations of a ¢nite
collection of modules [1].
One module present in a number of proteins is the type
A-domain, ¢rst described in von Willebrand factor (reviewed
in [2]). Members of the expanding von Willebrand factor type
A-domain (VA-domain) protein superfamily participate in a
variety of functions including hemostasis, cell adhesion and
interactions between matrix molecules. ECM components that
contain one or more VA-domains include collagens types VI
[3,4], VII [5], XII [6], XIV [7], XX [8] and XXI [9], matrilins-1,
-2, -3, -4 (reviewed in [10]), cochlin [11], polydom [12] and
nine transmembrane K-integrin chains (K1, K2, K10, K11,
KL, KM, KX, KD and KE) (reviewed in [13]) where they are
also known as ‘I’-domains.
The crystal structures for several VA-domains have been
solved [13^17] and show that the VA module is an indepen-
dently folding protein unit that attains a classic K/L ‘Rossman’
fold consisting of a parallel L-sheet surrounded by amphi-
pathic K-helices. The majority of VA-domains contain a metal
ion-dependent adhesion site (MIDAS) at the C-terminal end
of the L-sheet, however not all VA-domains contain this motif
[15]. Although the role of VA-domains in ECM proteins has
not been precisely determined, they appear to play important
roles in protein^protein interactions [18^20] and in multimeric
protein assembly [21,22] and may be crucial in providing link-
ages between ECM structural networks [23,24].
We have identi¢ed a new member of the VA-domain pro-
tein superfamily by interrogation of the mouse expressed se-
quence tag (EST) database. WARP, von Willebrand factor
A-domain-related protein, is a 415 amino acid modular pro-
tein containing a single VA-domain, two ¢bronectin type III
(F3) repeats and a short proline/arginine-rich C-terminal seg-
ment. Our data indicate that WARP is a novel, secreted ECM
glycoprotein expressed by chondrocytes.
2. Materials and methods
2.1. Identi¢cation of WARP cDNAs
The mouse EST database was conceptually translated into six read-
ing frames and interrogated with the 200 amino acid sequence of the
K3(VI) N8 VA-domain of human collagen VI [3] using the tblastn
programme (v2.0) at the National Center for Biotechnology Informa-
tion (NCBI). Several overlapping cDNA clones with signi¢cant sim-
ilarity to K3(VI) N8 at the protein level were identi¢ed and we ob-
tained three of these clones, ui42d08, ue22e08 and ml15f02 (Genome
Systems). DNA sequencing (Amplicycle sequencing kit, Perkin Elmer
Biosystems) revealed that clones ue22e08 (1026 bp) and mt15f02 (551
bp) lie entirely within the ui42d08 (2308 bp) sequence and exactly
matched the larger clone spanning nucleotides 1282^23081 and
1833^2227, con¢rming that the three cDNAs represent a single
gene. The collections of mouse and human WARP ESTs have been
assigned to the Unigene (http://www.ncbi.nlm.nih.gov/UniGene/) en-
tries Mm. 26515 and Hs. 110443 respectively.
2.2. WARP plasmid constructs and expression in transfected cells
The ui42d08 cDNA in pME18 (GenBank accession number
AI115125) (Fig. 1A) was subcloned into the pBluescript SK3 vector
(Stratagene) as a XhoI fragment and translated in vitro using the TNT
coupled transcription and translation system (Promega) [25] to con-
¢rm the open reading frame. To enable immunoprecipitation of
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WARP protein from transfected cells, a His-tagged full-length expres-
sion construct was also produced. Six histidine residues were incorpo-
rated at the N-terminus immediately following amino acid 21, be-
tween the signal peptide and the start of the VA-domain, by strand
overlap extension polymerase chain reaction (PCR) [25] and sub-
cloned into the pBluescript SK3 vector. To allow episomal expression
in mammalian cells, WARP-His was subcloned from pBluescript SK3
into pCEP4 (Invitrogen) as a XhoI fragment. WARP-His in pCEP4
was transfected into 293-EBNA cells (Invitrogen) grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) containing 10% bovine serum us-
ing FuGene transfection reagent (Roche) according to the manufac-
turer’s instructions and grown for 14 days in the presence of 250 Wg/
ml hygromycin B (Roche) to select for transfected cells.
2.3. Cell culture
Human embryonic kidney 293-EBNA cells, mouse MC3T3 osteo-
blast [26], Mov13 ¢broblast [27], 3T3 ¢broblast, C2C12 myoblast [28],
and C57 primary ¢broblast cell cultures were maintained in culture in
DMEM containing 10% bovine serum. Primary chondrocytes were
isolated as previously described [29]. Brie£y, rib cages were dissected
from newborn mice and incubated in DMEM containing 5% bovine
serum and 2 mg/ml collagenase (Worthington Biochemical Corp.) for
30 min at 37‡C. Loose connective tissue and bone was removed and
the rib cartilage incubated in fresh collagenase solution for 16 h.
Chondrocytes released from cartilage were centrifuged and grown as
a pellet culture for 16 h in DMEM containing 10% foetal calf serum
prior to RNA isolation.
2.4. mRNA expression analysis
Total RNA was isolated from mouse cell lines and primary rib
chondrocytes using the mini RNeasy1 RNA isolation kit (Qiagen)
according to the manufacturers instructions and from mouse tissues
using the guanidinium thiocyanate and phenol/chloroform method of
Chomzynski [30]. To ensure that no genomic DNA was carried
through the isolation procedure all RNA samples were digested
with DNA-free1 DNase treatment and removal kit (Ambion). Re-
verse transcription (RT)-PCR was performed using the GeneAmpR
RNA PCR kit (Perkin Elmer). 2 Wg of total RNA was added to each
RT reaction in a total volume of 40 Wl and 10 Wl of cDNA was used in
the subsequent PCR in a 50 Wl reaction volume. The optimal Mg2
concentration was found to be 0.35 mM for the WARP ampli¢cation
and 1 mM for the internal control, hypoxanthine guanine phosphor-
ibosyltransferase (HPRT), a housekeeping gene involved in purine
metabolism. In the PCR step, NR1 (16665P-CTCAAAGCCATGCG-
TAGTCC-3P1685), and NF4 (9535P-AGAACGCATCGTCATCTCGC-
3P972) primers were used to amplify a 693 bp region of WARP.
mHPRT1 (2315P-CCTGCTGGATTACATTAAAG-3P251) and
mHPRT2 (5815P-TCAAGGGCATATCCAACAAC-3P601) primers
were used to amplify a 350 bp fragment of the mouse HPRT gene
(GenBank accession number NM_013556). The cycle number for each
gene was selected so that ampli¢cation was in the linear range (not
shown), allowing the level of PCR products to be compared between
samples. Simultaneous ampli¢cation of HPRT derived from the same
cDNA reaction allowed correction for small variations in amount of
template.
For Northern blot analysis, 60 Wg of total RNA was poly(A)-se-
lected using oligo dT Dynabeads (Dynal), fractionated on a 1% (w/v)
agarose formaldehyde gel and transferred to Hybond N nylon mem-
brane (Amersham). A [32P]dCTP-labelled WARP probe was hybrid-
ised to the blot in Ultrahyb hybridisation solution (Ambion) at 42‡C
overnight. The blot was washed to a stringency of 0.1USSC/0.1%
sodium dodecyl sulphate (SDS) (w/v) at 65‡C, exposed to a phos-
phor-screen and scanned with a Storm phosphor-imager (Molecular
Dynamics).
2.5. WARP biosynthetic labelling and analysis
293-EBNA cells transfected with WARP were grown to con£uence
in a 60-mm dish and labelled for 16 h with 300 WCi of
L-[35S]methionine (1398 Ci/mmol, NEN Research Products) in
DMEM without L-methionine and L-cysteine (Life Technologies).
The medium was removed and centrifuged to pellet any cells and
NP-40 added to the supernatant to 1% (v/v) together with a cocktail
of protease inhibitors (1 mM 4-(2 aminoethyl)-benzenesulfonyl-£uo-
ride (AEBSF); 1 mM phenylmethylsulfonyl £uoride (PMSF); 20 mM
N-ethylmaleimide (NEM)). The cell layer was dispersed in 1 ml of
lysis bu¡er (150 mM NaCl; 50 mM Tris^HCl, pH 7.5; 5 mM
EDTA; 20 mM NEM; 1 mM AEBSF; 1 mM PMSF; 1% (v/v)
NP-40) on ice for 30 min then centrifuged brie£y to remove insoluble
material. Following a pre-clear step with 100 Wl protein G-Sepharose
(20% slurry in PBS), anti-His antibody (Roche) (1 in 100 dilution) was
added to each fraction together with 100 Wl fresh protein G-Sepharose
and mixed gently at 4‡C for 16 h. The antibody^Sepharose complex
was washed twice with 50% lysis bu¡er/50% NET (150 mM NaCl; 50
mM Tris^HCl, pH 7.4; 1 mM EDTA; 0.1% NP-40) for 30 min each
then twice with NET. Immunoprecipitated material was separated
from the Sepharose beads by heating at 65‡C for 15 min in SDS^
polyacrylamide gel electrophoresis (PAGE) sample bu¡er containing
20 mM dithiothreitol (DTT), fractionated on a 10% (w/v) SDS^poly-
acrylamide gel and subjected to £uorography.
2.6. N-glycosidase treatment
WARP-His protein was deglycosylated by N-glycosidase F (Roche)
treatment according to the manufacturers guidelines. Immunoprecipi-
tated WARP-His was denatured by boiling in 1% SDS for 2 min then
diluted 1 in 10 with sodium phosphate bu¡er (20 mM sodium phos-
phate, pH 7.2; 10 mM sodium azide; 50 mM EDTA; 0.5% (v/v) NP-
40) and boiled again for 2 min. Following addition of 0.4 units of
N-glycosidase F the sample was incubated for 20 h at 37‡C then heat
denatured in SDS^PAGE sample bu¡er containing 20 mM DTT and
analysed by SDS^PAGE.
2.7. SDS-PAGE
Samples were resolved on 10% (w/v) polyacrylamide separating gels
with a 3.5% (w/v) acrylamide stacking gel in the absence of urea as
described previously [25,31].
3. Results and discussion
3.1. Analysis of WARP sequences
To identify novel ECM proteins that contain VA-like do-
mains, the mouse EST database at the NCBI was searched
with the N-terminal N8 VA-domain of the K3 chain of human
collagen VI [3]. We identi¢ed several overlapping EST clones
that when fully sequenced clearly represent a novel gene that
contains a predicted VA-like protein module. The longest EST
clone, ui42d08, appeared to be full-length with a start methio-
nine codon at nucleotides 30^32 and an in-frame TGA stop
codon at 1275^1277, indicating an open reading frame of 1248
bp with 29 bp of 5P-untranslated region and 1063 bp of 3P-
untranslated region (refer to the WARP GenBank entry for
cDNA sequence, AAK38350). The 3P-end of the clone in-
cludes a poly(A) tail and a predicted polyadenylation site at
nucleotides 2279^2285. The full-length WARP cDNA was
transcribed and translated in vitro and SDS^PAGE analysis
demonstrated a single protein product indicating that no stop
codons were present within the open reading frame (data not
shown). Since the full-length WARP nucleotide and protein
sequences have not been previously reported and the VA-do-
main is related to, but distinctly di¡erent from, those de-
scribed in existing family members (Fig. 2A), we conclude
that this gene is a new member of the VA superfamily. We
named this gene WARP, for von Willebrand factor A-do-
main-related protein.
The human homologue of WARP was identi¢ed by search-
ing the genome data with the mouse WARP protein sequence.
A match with a predicted protein sequence (hypothetical pro-
tein FLJ22215) with very high homology to the mouse WARP
was found. The human WARP gene, which maps to chromo-
some 1p36.3 (contig NT_025635), is composed of four exons
each of which encodes a separate protein domain. The ¢rst
exon (73 bp in size) encodes the signal peptide, exon 2 (558
bp) the VA-domain, exon 3 (279 bp) the ¢rst F3 repeat and
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exon 4 (347 bp) the second F3 repeat, the P/R-rich C-terminal
segment and the 3P-untranslated region. These sequences are
clearly homologues of each other because they share 79%
amino acid identity and if conserved changes are considered,
share 95% identity.
The mouse WARP open reading frame encodes a 415 ami-
no acid protein with a predicted molecular weight of 45 kDa
although the human sequence is slightly larger with a three
amino acid (PRP) insertion in the C-terminal domain
(Fig. 1A). Both homologues contain an 18 amino acid signal
sequence with a cleavage site between Ala18 and Arg19 as
indicated by signal sequence prediction programme SignalP
(v2.0) (http://genome.cbs.dtu.dk/services/SignalP-2.0) [32]
(not shown). The signal sequence is followed by a VA-domain
of approximately 200 amino acids with a putative MIDAS
motif [13] and three potential O-linked sites at Ser148, Thr362
and Thr401, as predicted by NetOGlyc software (http://
genome.cbs.dtu.dk/services/NetOGlyc) [33] although only the
¢rst two are conserved in the human sequence (Fig. 1A).
Adjacent to the VA-domain are two F3 repeats of approxi-
mately 80 amino acids in length each containing a potential
N-linked glycosylation site at Asn264 and Asn359 that ¢ts the
consensus sequence NxS/T. The C-terminus at the end of the
second F3 repeat is 21 amino acids in length (24 in the human
sequence) and is rich in proline and arginine residues but did
not show homology to any other protein by extensive data-
base searching. The domain structure of the WARP proteins
is shown in Fig. 1B.
3.2. Similarity of WARP to other ECM proteins
The protein sequences of the two domains present in
WARP (VA and F3) were used to search the non-redundant
and conserved domain databases at NCBI. A high degree of
amino acid similarity exists between the WARP VA-domain
and those found in other ECM proteins with most similarity
to VA-domains present in the FACIT collagens XII, XIV [34]
and the recently described FACIT collagens XX [8] and XXI
[9], the matrilins [10] and cochlin [11] (Fig. 2A). The amino
acids within the MIDAS motif which are critical for ion bind-
ing, Asp40, Ser42, Ser44, Thr113 and Asp144, are conserved in
both mouse and human WARP although biochemical and
crystallographic studies are required to directly demonstrate
a functional MIDAS motif. In addition, the overall arrange-
ment of K-helices and L-sheets that form the important sec-
ondary structural framework [17] shared between all VA-like
domains is conserved in WARP. The two F3 repeats are less
conserved than the VA-domain, although the overall frame-
work of seven hydrophobic strands that form the L-sandwich
typical of F3 repeats is conserved [35] (Fig. 2B). The ¢rst F3
repeat, F3-1, is most similar to those found in tenascins and
collagen XIV and F3-2 is most similar to those in collagen VII
and the FACIT collagens (data not shown).
3.3. WARP mRNA is expressed in mouse chondrocytes
The sites of WARP mRNA expression were determined by
RT-PCR analysis using primers speci¢c for WARP and a
control, HPRT. cDNA template that was made from RNA
Fig. 1. Sequence and modular organisation of mouse and human WARP protein sequences. A: Deduced amino acid sequence of human and
mouse WARP. The predicted N-terminal signal sequence is boxed and the position of potential N-linked (Asn264 and Asn359) and O-linked
(Ser148 and Thr361) glycosylation sites conserved in both sequences are underlined. The conserved C-terminal cysteine residue (Cys393) available
for disul¢de bond formation is boxed. Alignments were performed using CLUSTALW (http://www.ch.embnet.org/software/ClustalW.html) [41].
Sites where amino acids are identical in both sequences are marked with an asterisk, conserved substitutions are marked with a colon and
semi-conserved substitutions with a full-stop. B: The modular structure of WARP is shown using standard symbols to represent conserved
ECM protein modules [42]. VA, VA-domain; F3, ¢bronectin type III repeat; P/R, proline- and arginine-rich segment. Approximate positions
of N- and O-linked glycosylation sites and Cys residue, conserved in both mouse and human sequences, are indicated.
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was isolated from various mouse tissues including heart, skel-
etal muscle, testis, brain and lung, and cell lines including
Mov13 ¢broblast, MC3T3 osteoblast, 3T3 ¢broblast, C2C12
myoblast cell lines, and primary cells including mouse rib
chondrocytes and skin ¢broblasts (Fig. 3A). To control for
variation between RT reactions, WARP and HPRT were am-
pli¢ed in separate reactions using the same template cDNA.
Following 36 cycles of ampli¢cation, a WARP PCR product
was present in chondrocyte RNA (upper panel, lane 6) but
not in any other tissue or cell line. The presence of a band
representing HPRT in all lanes (lower panel) indicates that for
all samples the starting RNA was intact and the RT reactions
were successful. To con¢rm WARP expression in chondro-
cytes, mRNA from chondrocytes isolated from newborn rib
cartilage was subjected to Northern blot analysis (Fig. 3B).
Following hybridisation to a WARP cDNA probe, a band
representing WARP was detected in chondrocytes (lane 1)
but not in Mov13 ¢broblasts, MC3T3 osteoblasts and
C2C12 myoblasts. WARP migrates as a 2.3 kb mRNA which
is in agreement with the size of the full-length WARP cDNA
which is 2308 bp in length. We conclude that WARP is ex-
pressed highest in chondrocytes and at a much lower level in
Fig. 2. Alignment of VA-domain and F3 repeats of WARP with homologous domains in other ECM proteins. Identical positions are shown
within dark boxes and conserved substitutions in grey boxes. Alignments were performed using CLUSTALW (http://www.ch.embnet.org/soft-
ware/ClustalW.html) [41] with some changes performed visually and shaded using BOXSHADE (http://www.ch.embnet.org/software/BOX_
form.html). A: Alignment of VA-domains from several ECM proteins. Sequences are mouse matrilin-2 (GenBank accession number
NP_058042, amino acids 55^221), matrilin-4 (NP_038620, 34^200), matrilin-3 (NP_034900, 76^242), matrilin-1 (NP_034899, 43^209), and
WARP (AAK38350, 32^195), and chicken collagen XIV (S78476, 1040^1204), collagen XX (AAK58847, 239^302), and cochlin (O42163, 160^
323), and human collagen XII (NP_004361, 138^301), collagen XXI (AAL02227, 35^196), and VLA-1 K-integrin (P56199, 142^316). Conserved
amino acids important for the MIDAS motif are indicated (#). B: Alignment of F3 repeats from a sample of ECM proteins. Sequences are
mouse WARP F3-domain 1 (AAK38350, 215^301) and 2 (308^394), human collagen XII (NP_004361, 726^810), L4-integrin chain (NP_000204,
1461^1548), ¢bronectin (P11276, 1635^1720) and tenascin R (2211329A, 867^951), and chicken collagen XIV (S78476, 627^711).
FEBS 25984 12-4-02
J. Fitzgerald et al./FEBS Letters 517 (2002) 61^6664
other tissues and cell lines although a more detailed immuno-
chemical analysis is required to determine whether WARP is
chondrocyte-speci¢c.
3.4. Expression of WARP in transfected cells
To determine whether the predicted signal sequence is func-
tional in directing WARP secretion from cells, and to deter-
mine if the putative N-glycosylation sites are utilised, a
WARP cDNA expression construct with a poly-His-tag in-
serted between the signal peptide and VA-domain was trans-
fected into 293-EBNA cells. The stably transfected cells were
labelled overnight with [35S]methionine and immunoprecipi-
tated with anti-His antibodies. No material was immunopre-
cipitated from untransfected 293-EBNA cells (Fig. 4, lanes
1 and 2) indicating that no endogenous proteins are recog-
nised by the anti-His antibody. In cells transfected with the
His-WARP cDNA, His-tagged WARP protein migrated as an
approximately 48 kDa band in both cell layer and media
fractions (lanes 3 and 4). The majority of WARP is detected
in the medium during these continuous labelling conditions,
suggesting that WARP is e⁄ciently secreted from cells and
functions in the ECM environment. When the immunopreci-
pitated material was resolved under non-reducing conditions,
a higher molecular weight form was present indicating that in
these cells WARP forms higher-order structures via reducible
disul¢de bonds. The higher molecular weight species migrates
at approximately 102 kDa suggesting that WARP assembles
into a disul¢de-bonded homo-dimer. Although both human
and mouse WARP protein sequences contain two C-terminal
Cys residues, only one is conserved in both species at Cys393.
Site-directed mutagenesis experiments will determine which
Cys residue participates in intermolecular disul¢de bond for-
mation. When WARP was subjected to N-glycosidase diges-
tion there was a mobility shift to approximately 45 kDa
indicating that WARP has one or more N-linked oligosac-
charide side chains (lane 6). The molecular weight of the de-
glycosylated protein is in good agreement with the predicted
molecular weight of 45 kDa. There are two possible N-glyco-
sylation sites at Asn254 and Asn359 located in similar positions
in the centre of each of the two F3 repeats in a loop region
between L-strands C and CP (Fig. 2B). Although we might
expect both sites to be equally available for glycosylation, our
data do not provide information on whether one or both of
these sites is glycosylated in vitro.
In this report we describe the identi¢cation and initial char-
acterisation of WARP, a secreted von Willebrand factor
A-domain-related protein, expressed by newborn mouse chon-
drocytes. The presence of a VA-domain identi¢es WARP as a
new member of the VA-domain superfamily of ECM proteins
whose other members include matrilins-1, -2, -3, and -4, col-
lagens VI, VII, XII, XIV, XX, and XXI, nine K-integrin
chains, cochlin and polydom. The domain organisation of
WARP is broadly similar to that of the matrilins (for review
see [10]) and the FACIT collagens [8,9,34]. The four matrilin
family members contain at least one VA-domain, a variable
number of epidermal growth factor repeats and a short C-ter-
minal domain. The C-terminus of matrilin-1 forms a coiled-
coil structure composed of a heptad repeat of hydrophobic
amino acids which directs the formation of matrilin multimers
[36]. Multimers are then stabilised by interchain disul¢de
bonds provided by two Cys residues present within the C-ter-
minus [37]. The C-terminal domain in WARP is not predicted
to form a coiled-coil structure of the type found in matrilins
because it does not contain a well-de¢ned heptad repeat of
hydrophobic residues. However the conserved Cys residue at
Cys393 at the end of the second F3 repeat, would be in a good
position to stabilise WARP oligomerisation and it is tempting
to speculate that the C-terminus of WARP is involved in the
formation of WARP oligomers.
The modular arrangement of a VA-domain adjacent to F3
repeat domains in WARP is relatively rare in ECM proteins
and found only in collagen VII, and the FACIT collagens
XII, XIV and XX. Collagens XII and XIV are present in
tissues rich in type I collagen and closely associate with the
surface of ¢brillar collagen [38] and have been proposed to
mediate the assembly and growth of collagen ¢brils [39,40]. It
has been proposed that this regulatory function involves the
Fig. 3. Expression of WARP mRNA in mouse tissues and cell lines.
A: RT-PCR analysis of WARP mRNA expression. Total RNA was
isolated from mouse tissues (lanes 1^6) and cell lines (lanes 7^11),
treated with DNase to remove contaminating genomic DNA, and
added to an oligo dT-primed RT reaction followed by PCR using
primers speci¢c for WARP (upper panel) and HPRT (lower panel).
B: Northern blot analysis of WARP. Poly(A) mRNA isolated from
primary mouse chondrocytes (lane 1), MC3T3 osteoblasts (lane 2),
Mov13 ¢broblasts (lane 3) and C2C12 myoblasts (lane 4) was frac-
tionated on a 1% agarose gel and transferred to nylon membrane.
The membrane was probed with [K-32P]dCTP-labelled WARP
cDNA fragment and exposed to X-ray ¢lm. The migration position
of RNA markers in kb is indicated on the left.
Fig. 4. In vitro expression of WARP. His-WARP cDNA in pCEP4
was transfected into 293-EBNA human embryonic kidney cells and
His-WARP protein was immunoprecipitated from cell layer (lanes 1
and 3) and medium (lanes 2, 4^6) fractions of untransfected control
293-EBNA cells (control, lanes 1 and 2) or 293-EBNA cells trans-
fected with His-WARP cDNA (His-WARP, lanes 3^6) using an
anti-His antibody. Sample digested with N-glycosidase F following
immunoprecipitation is shown in lane 6. All samples were reduced
with 20 mM DTT prior to SDS^PAGE except for sample in lane 5.
The migration position of protein molecular weight markers is indi-
cated on the left.
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lateral alignment of collagen triple helices with the FACIT
collagen N-terminal domains that contain the VA and F3
repeats extending out from the ¢bril surface in a position to
interact with other ¢brils. Future experiments will explore the
possibility that WARP VA- and F3-domains function in a
similar manner to mediate an interaction between WARP
and cartilage collagen II ¢brils.
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